Drugs / BP102
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06373133 | May 2024 → Nov 2026 expected | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05928780 | Jul 2023 → Mar 2024 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04856774 | Jun 2021 → Mar 2024 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07268040 | Dec 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07241767 | Nov 2025 → Nov 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07028281 | Jul 2025 → Dec 2028 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07061210 | Jul 2025 → Oct 2026 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06915142 | Apr 2025 → Dec 2026 expected | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06679673 | Dec 2024 → Dec 2025 overdue | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05749588 | Mar 2023 → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT04974957 | Aug 2021 → Feb 2022 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03666728 | Nov 2018 → Mar 2020 | lung neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03645876 | Nov 2018 → Apr 2019 | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05909332 | Jun 2023 → May 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05169801 | Jan 2018 → Oct 2019 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06754930 Background | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04856787 Background | Jun 2021 → Apr 2024 | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05179239 Comparator | Feb 2022 → Aug 2024 | cervical cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP102 | “E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w” NCT03805399 ↗ |
| Known as | bevacizumab | “A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer” NCT05179239 ↗1“BP102 (a bevacizumab biosimilar)” PMID 39676137 ↗ Dec 2024 |
| Action | Inhibit | “BP102 (anti VEGFR)” NCT05909332 ↗ |
| Modality | Monoclonal antibody | “BP102 is a humanized recombinant monoclonal IgG1 antibody.” NCT03645876 ↗ |
| Route | Intravenous | “SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week” NCT03645876 ↗ |